Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors

X
Trial Profile

A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atirmociclib (Primary) ; Fulvestrant (Primary) ; Letrozole (Primary) ; Palbociclib (Primary) ; PF-07248144 (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms KAT6
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Jun 2024 Results( As of 30 Sep 2023, n=35 pts) reporting the clinical safety, efficacy, PK, PD, and biomarker study of PF-07248144, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2023 Results (At data cut off 30 Sep 2022, n=29)presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 25 May 2023 According to a Pfizer media release, data from this study will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2-6.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top